Skip to main content
Offcanvas
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.
What are you looking for?

Investing for Launch Success: Tailoring Your Strategy for Europe

Article

New analysis of success factors for emerging, small-sized and large biopharma companies launching in Europe. 

Europe is the second-largest global market after the US in drug development. Owing to this size and share, pharmaceutical companies both large and emerging usually prioritize the US followed by the top 5 European countries when launching products.  

Getting the launch is crucial as it drives the overall commercial success of the product, which in turn leads to optimizing a company’s return on investments. 

Despite Europe’s significance, an extensive launch analysis done by Syneos Health® estimates that approximately 90% of products launched by emerging or small-sized pharma companies and 60% of products launched by large pharma were unable to meet post-launch market expectations in European territories. 

Download the article below to learn how biopharma companies can evaluate and analyze the nuanced requirements of any market to customize a holistic and robust investment approach in Europe. 


Interested in Syneos Health?